Nasal naloxone 'inferior' for reversing overdose
This story has been updated to clarify that the naloxone formulations used in the trial were prepared specifically for the trial and were not approved therapeutic products on the Australian market. The study did not use the branded nasal spray Nyxoid, which is PBS-listed.
Nasal delivery of naloxone hydrochloride is inferior to intravenous injection in reversing opioid overdose, despite being the easier dispensing method, an Australian study confirms.
But researchers say while an optimal dose and